JAAD Case Reports · 2018 · 75 citations · 4 references
MedicineDermatologyPharmacotherapyDermatopathologyImmunopathologyRheumatologyAutoimmune Skin DiseasesFibrosisImmunopathology Of SkinInflammatory DermatosesInflammatory Skin DiseasesInflammatory Skin DisordersCutaneous Graft-versus-host DiseaseEosinophilic Skin DisordersJak Inhibitor TherapyJanus Kinase Inhibitor TherapyRetrospective Case StudyScleroderma TreatmentSclerosing TherapySkin Fibrosis
Morphea is a fibrosing skin disease with a spectrum of presentations ranging from localized indurated plaques to circumferential involvement of limbs that impairs mobility.1 Eosinophilic fasciitis (EF) is often considered a severe form of morphea.1 Treatment of severe sclerosing diseases, such as generalized deep morphea (GDM) and EF, can be challenging. Methotrexate and prednisone are therapeutic mainstays but are not effective in all cases.1 A recent retrospective study showed that ruxolitinib, a Janus kinase (JAK)1/2 inhibitor, was effective in treating sclerodermatous cutaneous graft-versus-host disease.
4
Suzanne C. Li, Kathryn S. Torok, Elena Pope et al. · Arthritis Care & Research · 2012 · 211 citations · Full text
Medicine, Dermatology, Pediatrics +14